Postinduction approaches for infant ALL in 3 major cooperative groups on most recent trials
| . | Interfant* . | COG . | JPLSG . |
|---|---|---|---|
| Trial | Interfant-06 | AALL0631 | MLL-10 |
| Randomized postinduction intervention | Protocol IB vs ADE/MAE | ±Lestaurtinib (FLT3 tyrosine kinase inhibitor) | None (single arm) |
| HSCT | All high risk, plus MRD+ after MARMA | None | All high risk |
| . | Interfant* . | COG . | JPLSG . |
|---|---|---|---|
| Trial | Interfant-06 | AALL0631 | MLL-10 |
| Randomized postinduction intervention | Protocol IB vs ADE/MAE | ±Lestaurtinib (FLT3 tyrosine kinase inhibitor) | None (single arm) |
| HSCT | All high risk, plus MRD+ after MARMA | None | All high risk |
Protocol IB consolidation indicates cyclophosphamide 1000 mg/m2 days 1 and 29; cytarabine 75 mg/m2 days 3 to 6, 10 to 13, 17 to 20, 24 to 27; 6-mercaptopurine 60 mg/m2 days 1 to 28 consolidation. ADE/MAE consolidation indicates cytarabine 100 mg/m2 every 12 hours days 1 to 10; daunorubicin 50 mg/m2 days 1, 3, and 5; etoposide 100 mg/m2 days 1 to 5/mitoxantrone 12 mg/m2 days 1, 3, and 5; cytarabine 100 mg/m2 every 12 hours days 1 to 10; etoposide 100 mg/m2 days 1 to 5. MARMA indicates methotrexate 5000 mg/m2 days 1 and 8; 6-mercaptopurine 25 mg/m2 days 1 to 14; cytarabine 3000 mg/m2 every 12 hours days 15, 16, 22 and 23; pegylated asparaginase 2500 IU/m2 day 23.